Do Investors Have Much Faith In Myriad Genetics, Inc. (NASDAQ: MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) does about 711.82K shares in volume on a normal day but saw 1041291 shares change hands in Tuesday’s trading. The company now has a market cap of 2.30B USD. Its current market price is $25.36, marking an increase of 1.72% compared to the previous close of $24.93. The 52 week high reached by this stock is $25.95 whilst the lowest price level in 52 weeks is $13.82.

Myriad Genetics, Inc. (MYGN) has a 20-day trading average at $20.49 and the current price is -2.27% off the 52-week high compared with 83.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $20.93 and its 200-day simple moving average is $19.12. If we look at the stock’s price movements over the week, volatility stands at 5.26%, which decreases to 4.18% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 75.13 to suggest the stock is overbought.

The consensus objective for the share price is $24.17, suggesting that the stock has a potential downside of -4.92% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 08, 2024 when Leerink Partners upgraded the stock to “Outperform” and issued a price target of between $25 and $35. Wells Fargo initiated its price target at $20.

Myriad Genetics, Inc. (MYGN) stock is up 28.21% over the week and 32.29% over the past month. Its price is 32.50% year-to-date and 42.23% over the past year.

To reach the target analysts have set, the stock logically needs to shrink -4.92 percent from here.

The company has a return on investment of -26.27% and return on equity of -29.41%. The forward price to earnings ratio is 113.98. The beta has a value of 1.97. Price to book ratio is 3.02 and price to sales ratio is 2.96.